Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of E-52862 to prevent oxaliplatin-induced peripheral neuropathy in colorectal cancer
2012-000398-21Phase 2Completed
- Sponsor
- Esteve
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in peripheral neuropathy (CIPN) and neurotoxicity comparing E-52862 arm with Placebo arm (2 arms). Primary endpoints: Incidence of oxaliplatin-induced chronic peripheral neuropathy and Severity of oxaliplatin-induced chronic peripheral neuropathy. Started Apr 2012; status: completed.
02
Drugs
E-52862
03
Conditions
peripheral neuropathy (CIPN)neurotoxicity
Beyond the preview
Go deeper on 2012-000398-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000398-21.